Targeted therapy plus chemo vs chemo alone for stage 3 stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding disitamab vedotin (a drug that targets HER2) to standard chemotherapy (SOX) after surgery for stage 3 stomach cancer. The goal is to see if the combination works better than chemo alone to prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had surgery to remove your stomach cancer and nearby lymph nodes, and all visible cancer was removed.
- Your cancer was stage 3 at tumor testing and shows moderate to high levels of HER2 (a protein that helps some cancers grow).
- You have not had any cancer treatment before surgery, like chemo or targeted therapy.
- You are in good general health and able to perform daily activities without help (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three drugs (disitamab vedotin, tislelizumab, and chemotherapy) compared to two of them (tislelizumab plus chemotherapy) for people with advanced stomach or gastroesophageal junction cancer that has low levels of a protein called HER2. It aims to see if adding the third drug helps shrink or control the cancer better.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests whether adding immunotherapy to chemotherapy after surgery for stomach or gastroesophageal junction cancer helps prevent the cancer from coming back. It is for people whose cancer is HER2-negative and who have had the tumor completely removed.
This trial compares two chemotherapy combinations (oxaliplatin plus S-1 vs docetaxel plus S-1) for people with stage III stomach cancer who have had complete surgical removal of the tumor. The goal is to see which combination works better to prevent cancer from returning.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new GC/GEJC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.